Natural killer group 2 member D receptor–ligand interaction (NKG2D–ligand interaction (NKG2D/NKG2DL axis))

The **natural killer group 2 member D receptor–ligand interaction** refers to the binding between the activating immune receptor **NKG2D**—expressed primarily on natural killer (NK) cells as well as subsets of T lymphocytes—and its diverse set of cell-surface ligands. These ligands include **MHC class I polypeptide-related sequence A/B (MICA/B)** and members of the **UL16-binding protein family** (*ULBP* 1–6), also known as *RAET1* proteins. The expression of these ligands is typically low on healthy tissue but is strongly upregulated under cellular stress conditions such as infection, transformation into cancerous states, DNA damage response activation, senescence, or inflammation. Upon engagement with its ligand(s), NKG2D transmits potent activating signals that trigger cytolytic activity—release of perforin/granzymes—and cytokine production from NK/T effector cells. This mechanism plays a central role in tumor surveillance by eliminating transformed/cancerous cells before they become clinically apparent; it is also crucial for antiviral defense. However, dysregulation can contribute both to beneficial effects—such as enhanced anti-tumor immunity—or pathological consequences like autoimmunity or transplant rejection if normal tissues aberrantly express these stress-induced markers. Tumors may evade this surveillance through shedding soluble forms (“decoys”) that downregulate surface NKG2D expression on effectors. The pathway’s complexity makes it an attractive but challenging therapeutic target for cancer immunotherapy and transplant medicine.[1][3][4]

Other names

NKG2D–ligand axisNKG2D receptor/ligand systemKLRK1–NKG2DL interactionNatural killer group 2, member D and ligand interaction

Drugs or biologics targeting this molecule would typically act by either blocking or enhancing the binding between NKG2D receptors on immune effector cells (NK cells, CD8+ T cells) and their ligands on target/stressed/tumor/infected cells. This can result in increased killing of target cells or modulation of immune responses depending on therapeutic intent.[1][4]